Literature DB >> 19664362

Alemtuzumab versus interferon beta-1a in early multiple sclerosis.

Dennis Bourdette1, Vijayshree Yadav.   

Abstract

Entities:  

Year:  2009        PMID： 19664362     DOI： 10.1007/s11910-009-0062-1

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


× No keyword cloud information.
  6 in total

Review 1.  Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D S Goodin; B A Cohen; P O'Connor; L Kappos; J C Stevens
Journal:  Neurology       Date:  2008-09-02       Impact factor: 9.910

2.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

3.  Daclizumab in treatment of multiple sclerosis patients.

Authors:  E N Ali; B C Healy; L A Stazzone; B A Brown; H L Weiner; S J Khoury
Journal:  Mult Scler       Date:  2009-01-09       Impact factor: 6.312

4.  Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.

Authors:  J W Rose; J B Burns; J Bjorklund; J Klein; H E Watt; N G Carlson
Journal:  Neurology       Date:  2007-08-21       Impact factor: 9.910

5.  Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

Authors:  Bibiana Bielekova; Thomas Howard; Amy N Packer; Nancy Richert; Gregg Blevins; Joan Ohayon; Thomas A Waldmann; Henry F McFarland; Roland Martin
Journal:  Arch Neurol       Date:  2009-04

6.  Alemtuzumab in chronic lymphocytic leukemia.

Authors:  G Fraser; C A Smith; K Imrie; R Meyer
Journal:  Curr Oncol       Date:  2007-06       Impact factor: 3.677
  6 in total
  1 in total

1.  New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.

Authors:  J Nicholas; B Morgan-Followell; D Pitt; M K Racke; A Boster
Journal:  J Cent Nerv Syst Dis       Date:  2012-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.